학술논문

Therapeutic innovation for multi-resistant candidemics: synergy of isavuconazole and caspofungin association
Document Type
article
Source
Hematology Reports, Vol 13, Iss 4 (2021)
Subject
Fungal infection
Candida
isavuconazole
caspofungin
combined antifungal therapy
hematological patients
Diseases of the blood and blood-forming organs
RC633-647.5
Language
English
ISSN
2038-8322
2038-8330
Abstract
Fungal infections occurring in immunocompromised patients after immuno-chemotherapy treatment, are often difficult to eradicate and capable of even being fatal. Systemic mycoses affecting severely immunocompromised patients often manifest acutely with rapidly progressive pneumonia, fungemia, or manifestations of extrapulmonary dissemination. Opportunistic fungal infections (mycoses) include several pathogens elements, as Candidiasis, Aspergillosis, Mucormycosis (zygomycosis) and Fusariosis. Prompt diagnosis and effective therapy are needed to improve the associated morbidity and mortality, especially in cases with non-canonical fungal localizations and not responsive to the available antifungal drugs.